Odyssey Therapeutics, Inc. · NASDAQ:ODTX
Odyssey Therapeutics — Investor Presentation (June 2026)
40 slides from Odyssey Therapeutics's investor presentation, Jun 23, 2026
Slide 1: Corporate Presentation June 2026
Corporate Presentation June 2026
Slide 2: Confidential information, forward-looking statements, and third-party information
Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, Inc. (the “Company,” “Odyssey,” “we,” or “us”) and its subsidiari
Slide 3: Despite Decades of New Therapies, Few Patients With Autoimmune Disease Have Durable Remission
Despite Decades of New Therapies, Few Patients With Autoimmune Disease Have Durable Remission Patients need: Increased remissions and more treatable diseases Deep and durable disease-modifying responses Better safety and tolerability with reduced infection risk Anti-Inflammatory 1970s Steroid-Sparin
Slide 4: Unlocking Durable Remissions by Targeting the Upstream Root of Disease
Unlocking Durable Remissions by Targeting the Upstream Root of Disease Defined pathogenic triggers underlie inflammatory disease… … by converging on disease-specific signaling nodes… … initiating a broad cytokine and immune response… …causing tissue damage and disease Cytokines & chemokines Inflamma
Slide 5: Experienced Team and Organization to Maximize Success
BOARD OF DIRECTORS Experienced Team and Organization to Maximize Success Gary Glick, Ph.D. Founder and CEO Tony Opipari, M.D., Ph.D. Interim Chief Medical Officer Joe McDonald, Ph.D. Chief Data Officer Natalie Dales, Ph.D. Research Operations Steve Soisson, Ph.D. Protein Therapeutics Bill Roush, Ph.
Slide 6: Pioneering Next Generation I&I Therapies to Redefine Standard of Care
Pioneering Next Generation I&I Therapies to Redefine Standard of Care Current market: $100B INFLAMMATORY BOWEL DISEASE B CELL-MEDIATED DISEASES INFLAMMATORY AND AUTOIMMUNE DISEASES Differentiated first-in-class, oral, monotherapy with positive safety profile Potential first-in-class, oral therapy to
Slide 7: Broad Therapeutic Pipeline for Diseases With Unmet Need
Broad Therapeutic Pipeline for Diseases With Unmet Need Notes: UC = ulcerative colitis; CD = Crohn’s disease; CLE = cutaneous lupus erythematosus; AD = atopic dermatitis; SLE = systemic lupus erythematosus; COPD = chronic obstructive pulmonary disease. Target Modality Indications Discovery IND-Enabl
Slide 8: Data to Build a Potential RIPK2 IBD Franchise Expected by 2028
2028 Data to Build a Potential RIPK2 IBD Franchise Expected by 2028 Monotherapy induction efficacy Break therapeutic ceiling through innate-adaptive combinations for induction Demonstrate potential of RIPK2-only monotherapy as next SoC maintenance therapy Note: * Trial initiation expected in 2H 2026
Slide 9: Oral RIPK2 Scaffolding Inhibitor: OD-001
Oral RIPK2 Scaffolding Inhibitor: OD-001 Addressing a Root Cause of Inflammation in IBD Using a Novel Mechanism of Action Proof-of-Concept Achieved in Ulcerative Colitis Program Inception to Phase 2 Proof-of-Concept: 4.5 Years
Slide 10: IBD Is Driven by Innate Immune Cells Responding to Gut Bacteria
IBD Is Driven by Innate Immune Cells Responding to Gut Bacteria Breakdown of the gut lining and exposure of innate immune cells to bacteria are a root cause of IBD Gut lumen Activated T cells T cells TNF IL-23 Activation of neutrophils continues breakdown of gut lining TL1A Th1 Th17 Innate immune ce
Slide 11: Even With Advanced Therapies, Durable Remission Rates for IBD Remain Low
miR-124 Even With Advanced Therapies, Durable Remission Rates for IBD Remain Low ~75% of patients fail to achieve clinical remission 45% of patients who achieve remission progress within five years (1,2) Sources: (1) Clin Gastroenterol Hepatol 2015;13(3):531; (2) World J Clin Cases 2024;12(10):1718;
Slide 12: We Believe RIPK2 Is a Validated and Ideal Target for Treating IBD
We Believe RIPK2 Is a Validated and Ideal Target for Treating IBD Sources: Inflamm Bowel Dis 2015;21(4):862; J Med Chem 2022;65(13):9312; J Med Chem 2019;62(14):6482; Proc Natl Acad Sci 2014;111(25):E2559; Am J Physiol 2021;321(5):G500; Commun Biol 2020;3(1):140; J Med Chem 2016;59(10):4867; Int Imm
Slide 13: RIPK2 Is Activated in UC and Crohn's Disease and Correlates With Severity
Increased expression of RIPK2-dependent gene signature in UC and CD patient biopsies RIPK2 Is Activated in UC and Crohn’s Disease and Correlates With Severity Notes: *** = p ≤ 0.0001; GSVA = gene set variation analysis; GSVA cut-off for % of UC or CD patients with RIPK2 pathway activity is 0.46 or 0
Slide 14: OD-001 Blocks Multiple Cytokines That are Validated IBD Drug Targets
Effect on cytokine production from macrophages stimulated with PGN OD-001 Blocks Multiple Cytokines That are Validated IBD Drug Targets with Similar Effect in Samples from AT-Experienced or AT-Naïve Patients TNF IL-23 TL1A % Inhibition OD-001, nM 0.01 0.1 1 10 100 0 20 40 60 80 100 TNF naïve TNF res
Slide 15: OD-001 Has The Potential To Improve Outcomes By Overcoming Resistance to Standard of Care
OD-001 Has The Potential To Improve Outcomes By Overcoming Resistance to Standard of Care or Use as a Combination Partner Notes: GSVA = gene set variation analysis; NR = Non-Responder; gene expression datasets utilized = GSE73661; infliximab and vedolizumab datasets used inflamed mucosal tissue; ***
Slide 16: Phase 2a Monotherapy Trial Overview
Enrolled patients with moderate-to-severe UC, modified Mayo Clinical score (MMCS) of 5–9; allowed up to 3 prior advanced therapies Both doses expected to be active based on Phase 1 ex vivo TNF release assay Features and strategies to minimize placebo effect: Required endoscopic subscore (Mayo endosc
Slide 17: Enrolled Participant Characteristics Are Similar to Contemporary UC Trials
Enrolled Participant Characteristics Are Similar to Contemporary UC Trials Notes: (1) Includes both approved advanced therapies and investigational agents; includes golimumab, etrasimod, ustekinumab, rosnilimab, MORF-057, PN-943, infliximab, icotrokinra, TYK2 inhibitor, adalimumab, and etrolizumab.
Slide 18: OD-001 Was Well Tolerated With a Promising Safety Profile Observed
OD-001 Was Well Tolerated at 10 mg BID and 20 mg BID With a Promising Safety Profile Observed Disclaimer: Data presented are from ongoing studies, which will not be finalized until database lock. Thus, these data are subject to change prior to release of the clinical study report (“CSR”). Notes: (1)
Slide 19: Trial Met Key Efficacy Endpoints, Including Clinical Remission
Trial Met Key Efficacy Endpoints, Including Clinical Remission Met primary endpoint of change in MMCS from baseline in both parts and on a consolidated basis (-2.6, p < 0.001) Disclaimer: Data presented are from ongoing studies, which will not be finalized until database lock. Thus, these data are s
Slide 20: Clinical Remission Rates in AT-Experienced vs. AT-Naïve Patients
Clinical Remission Rates in AT-Experienced vs. AT-Naïve Patients Disclaimer: Data presented are from ongoing trial, which will not be finalized until database lock. Thus, these data are subject to change prior to release of the CSR. Future results may differ from those shown here. Notes: OD-001 resu
Slide 21: Rapid Onset of Action With Deepening of Response, Consistent with MoA
Disclaimer: Data presented are from ongoing studies, which will not be finalized until database lock. Thus, these data are subject to change prior to release of the CSR. Note: OD-001 results are consolidated from both part 1 and part 2. Rapid Onset of Action With Deepening of Response, Consistent wi
Slide 22: Patient Vignette A: Clinical Remission in AT-Experienced Patient
Week 1 Week 6 OD-001 start Patient Vignette A: Clinical Remission in AT-Experienced Patient Disclaimer: (1) While we believe the observations derived from this patient’s results are informative, the results depicted are preliminary results from a single patient and may not be replicated in other pat
Slide 23: Patient Vignette B: Clinical Remission With OD-001 but Relapse on Vedolizumab
OD-001 start OD-001 stop Vedolizumab start 55-year-old Canadian female with 5-year history of UC Patient was previously treated with anti-IL-23 and S1P1 MES of 2 and MMCS of 5 at screening Achieved clinical remission and histologic endoscopic mucosal improvement (HEMI) at week 12; worsening after OD
Slide 24: OD-001 Is the First Innate Immune-Targeted Therapy for IBD
OD-001 Is the First Innate Immune-Targeted Therapy for IBD Efficacy is competitive with leading approved or investigational therapies Concordant efficacy measures across all endpoints, consistent with the mechanism of action for RIPK2 Strong efficacy in AT-experienced patients Innate immune cells (e
Slide 25: Multiple Opportunities for OD-001 to Establish a Leading IBD Franchise
Multiple Opportunities for OD-001 to Establish a Leading IBD Franchise Conventional therapy Phase 2a vedolizumab combination induction results expected in 2H 2027 Phase 2b monotherapy induction expected in 2H 2027 and monotherapy maintenance results expected in 2028 Expansion of addressable populati
Slide 26: Oral SLC15A4 Inhibitor: OD-002
Oral SLC15A4 Inhibitor: OD-002 Modulating B Cell Activity and Interferon Signaling IND-Enabling Studies Ongoing Program Inception to GLP Studies: 15 Months
Slide 27: RNA and DNA Signaling Pathways Converge on SLC15A4 to Activate IRF5
RNA and DNA Signaling Pathways Converge on SLC15A4 to Activate IRF5, a Master Regulator of Autoimmune Responses Extracellular RNA and DNA signal via TLR7/8/9… … through SLC15A4 to activate IRF5… … inducing pathogenic B cells and inflammatory cytokines… …causing disease Myeloid cells produce type I i
Slide 28: SLC15A4 Development Candidate, OD-002, Observed to Address Multiple Aspects of Autoimmune Pathogenesis
OD-002 is potent and selective with favorable druglike properties OD-002 reduced pathogenic B cell populations and autoantibody production SLC15A4 Development Candidate, OD-002, Observed to Address Multiple Aspects of Immune Cell-Mediated Autoimmune Pathogenesis Notes: **** = p < 0.0001. 7–9-week-ol
Slide 29: Potential for CAR-T-Like Modulation of Pathogenic B Cells in a Pill
Potential for CAR-T-Like Modulation of Pathogenic B Cells in a Pill Academic or hospital setting only Persistent inhibition of expansion and activation by RNA and DNA Outpatient setting CD19 and BCMA-targeted CAR-T therapy OD-002 TARGET Broad B cell depletion Removes healthy and pathogenic B cells T
Slide 30: Phase 1/2a Trial Initiation Expected in 1H 2027 With Proof-of-Concept Expected in 2H 2028
Phase 1/2a Trial Initiation Expected in 1H 2027 With Proof-of-Concept Expected in 2H 2028 Small patient cohorts: 12-week treatment in CLE and 1–2 additional indications SAD: ~6 dose levels MAD: ~4 dose levels Food effect: ~1 dose level 1H 2027 2H 2027 2H 2028 Phase 2a: Patient groups Phase 1: Random
Slide 31: TNFR2 Agonist: OD-003
TNFR2 Agonist: OD-003 Modulating Treg to Treat Autoimmune and Inflammatory Disease IND-Enabling Studies Ongoing
Slide 32: Treg Therapy Has Broad Therapeutic Potential in Large I&I Diseases
Treg Therapy Has Broad Therapeutic Potential in Large I&I Diseases Correcting Treg dysregulation or increasing the number of Treg has the potential to be used across many inflammatory and autoimmune diseases Atopic dermatitis SLE Alopecia areata Multiple sclerosis Rheumatoid arthritis Asthma EFFECT
Slide 33: TNFR2 Agonism Is Next Evolution of Treg-Targeted Therapy
TNFR2 agonism clinical PoC upcoming to unlock next stage of Treg therapy development Expanding Treg number observed to be effective in multiple diseases TNFR2 agonism can potentially address the shortcomings of IL-2 TNFR2 Agonism Is Next Evolution of Treg-Targeted Therapy Note: *** p < 0.001. Source
Slide 34: Treg Therapy Has Potential to Transform Some of the Largest I&I Indications
CLINICAL SIGNAL Rezpeg-treated AD patients with self-reported asthma history showed improvement in asthma control questionnaire (ACQ-5) scores ~$25B Respiratory Asthma MECHANISTIC EVIDENCE Treg maintain intestinal immune tolerance and mucosal integrity; Treg dysregulation contributes to chronic infl
Slide 35: Final Words
Final Words —Yy 2 Q (CA Copyright 2026 | Odyssey Therapeutics | All Rights Reserved In search of extraordinary for patients 35
Slide 36: Significant Clinical Milestones Expected Through 2028
Significant Clinical Milestones Expected Through 2028 2026 2027 2028 1H: Initiate OD-002 healthy participant dosing in Ph1/2 trial 2H: Complete OD-002 healthy participant dosing in Ph1/2 trial 2H: OD-001 phase 2a vedolizumab combination induction readout 2H: OD-001 phase 2b monotherapy induction rea
Slide 37: Odyssey Therapeutics
ODYSSEY THERAPEUTICS
Slide 38: Appendix
Appendix —Yy 2 Q (CA Copyright 2026 | Odyssey Therapeutics | All Rights Reserved In search of extraordinary for patients 38
Slide 39: Similar Activity Observed Across Efficacy Measures in Part 1 and Part 2 in Phase 2a
Similar Activity Observed Across Efficacy Measures in Part 1 and Part 2 in Phase 2a Monotherapy Trial of OD-001 Disclaimer: Data presented are from ongoing studies, not finalized until database lock and, thus, are subject to change prior to release of the CSR. Future results may differ from those sh
Slide 40: Placebo Clinical Remission Rates Are Generally Similar Across Regions
Placebo Clinical Remission Rates Are Generally Similar Across Regions Source: Scaldaferri F, Seidler U, Treton X, et al. ECCO 2026; P1159. Eastern European patients (n = 479) Global patients (n = 1,272) n/N = 4/71 8/77 26/137 Western European patients (n = 285) n/N = 5/110 28/125 54/244 n/N = 14/317
Odyssey Therapeutics — Investor Presentation (June 2026) on 6ix